Inhibitor Therapeutics Inc
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal… Read more
Inhibitor Therapeutics Inc (INTI) - Total Liabilities
Latest total liabilities as of September 2025: $3.13 Million USD
Based on the latest financial reports, Inhibitor Therapeutics Inc (INTI) has total liabilities worth $3.13 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Inhibitor Therapeutics Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Inhibitor Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Inhibitor Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Inhibitor Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
McLaren Resources Inc
F:3ML
|
Germany | €378.29K |
|
HOCHDORF HLDG AG
F:1Z3
|
Germany | €781.00K |
|
Merida Minerals Inc.
V:ESPN
|
Canada | CA$3.24 Million |
|
Grand Gulf Energy Ltd
AU:GGE
|
Australia | AU$706.41K |
|
Planet Ventures Inc
PINK:PNXPF
|
USA | $6.99 Million |
|
Beam Communications Holdings Ltd
AU:BCC
|
Australia | AU$3.61 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Inhibitor Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 35.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 906.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inhibitor Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inhibitor Therapeutics Inc (2015–2024)
The table below shows the annual total liabilities of Inhibitor Therapeutics Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.71 Million | +1.21% |
| 2023-12-31 | $3.67 Million | -0.37% |
| 2022-12-31 | $3.68 Million | -0.02% |
| 2021-12-31 | $3.68 Million | +5.37% |
| 2020-12-31 | $3.49 Million | +1.77% |
| 2019-12-31 | $3.43 Million | +185.77% |
| 2018-12-31 | $1.20 Million | +99.61% |
| 2017-12-31 | $601.49K | +95.20% |
| 2016-12-31 | $308.13K | -33.29% |
| 2015-12-31 | $461.88K | -- |